Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
Encouraged by remarkable successes in preventing infectious diseases and by the well-established potential of the immune system for controlling tumor growth, active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, engineered recombinant viral vectors have been carefully examined as genetic-immunization vehicles and have been demonstrated to induce potent T-cell-mediated immune responses that can control tumor growth. Very recent efforts suggest that lentivectors possess important advantages over other candidate recombinant viral vectors for genetic immunization. Here, we review the development of recombinant lentivectors and the characteristics of T-cell immune responses elicited by lentivector immunization, including the mechanism of T-cell priming with a focus on the role of skin dendritic cells and potential applications for tumor immunotherapy.
He
Yukai
Y
Medical College of Georgia, Immunology/Immunotherapy Program, MCG Cancer Center, CN-4150, 1120 15th Street, Augusta, GA 30912, USA. yhe@mcg.edu
Munn
David
D
Falo
Louis D
LD
D000818:Animals; D019496:Cancer Vaccines / Q000235:genetics* / Q000276:immunology* / Q000627:therapeutic use; D005822:Genetic Vectors / Q000235:genetics* / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D016086:Lentivirus / Q000235:genetics* / Q000276:immunology*; D014611:Vaccination / Q000379:methods* / Q000639:trends; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use
D019496:Cancer Vaccines; D014614:Vaccines, Synthetic